
Lam Research Corporation (LRCX), a large-cap growth stock in the Semiconductors industry, received an 86% rating from Validea's Warren Buffett-inspired 'Patient Investor' model. This high score, indicating significant interest, is attributed to LRCX's strong fundamentals, including predictable earnings, low debt, robust free cash flow, and a reasonable valuation, aligning with criteria for long-term predictable profitability.
Lam Research Corporation (LRCX) screens favorably under Validea's 'Patient Investor' model, which emulates the investment principles of Warren Buffett. The company achieved an 86% rating, a score indicating significant interest based on the model's criteria for long-term predictable profitability, low debt, and reasonable valuation. The analysis highlights LRCX's fundamental strengths, as it passed key tests for earnings predictability, debt service, return on equity, free cash flow generation, and effective use of retained earnings. Furthermore, the company's active share repurchase program is viewed positively by the model. The sole point of weakness identified in this specific screen is the company's failure to meet the 'Return on Total Capital' threshold. Despite being classified as a large-cap growth stock within the competitive semiconductor industry, these results suggest LRCX exhibits strong value characteristics and financial discipline.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment